RT @atai_life: We’re proud to support @MGHNeurology and their Center for the Neuroscience of Psychedelics. The atai Research #Fellowship is….

Edit: interesting read on Zuranalone RWE:

12/12 - Some Initial thoughts and take-away.Great news for mothers living with PPD who might get a differentiated treatment option available soon. As we need to expect some regression to mean in subsequent larger RE104 Ph3 + Zuranolone was approved with solid pbo adj Δ of -4.2.

11/12 - Read‑across caveats (why you can’t compare point‑for‑point).Different endpoints/timepoints/scales (RE104: MADRS Day 7 vs brex: (mostly) HAM‑D 60 h), different controls (active low‑dose vs placebo), settings (at home oral vs outpatient SC vs inpatient 60‑h IV), severity.

10/12 - Zuranolone (oral) Phase 3 results.30 mg oral Zuranolone nightly for 2 weeks demonstrated significant day 15 HAMD-17 score improvements from baseline vs placebo (-17.8 vs -13.6; pbo adj delta of -4.2 (P=0.003), persisted through day 45, and response/remission rates

9/12 - Brexanolone (IV) Ph3 results (two pivotal RCTs).Across two multicenter RCTs (total n = 246), placebo‑adjusted LS mean HAM‑D (No MADRS available) differences at 60 h were :.• Study 1: −5.5 (60 µg/kg/h) and −3.7 (90 µg/kg/h) vs placebo (both p < 0.03).• Study 2:

8/12 - Brexanolone Ph2 Response, Remission, AEs.Remission at 60 h: 70% vs 9% (placebo); benefit persisted to Day 30. AEs mostly dizziness/somnolence; no SAEs

7/12 - Brexanolone Ph2 HAM-D and MADRS.At 60 h: −21.0 vs −8.8 HAM‑D (drug vs placebo), Δ = −12.2 (p = 0.0075). Pbo adj MADRS delta was also assessed: -16 at both 60h and Day 7.

6/12 - Brexanolone Ph2 design .Randomized, double‑blind, placebo‑controlled inpatient trial; n = 21 women ≤ 6 months postpartum with severe PPD (HAM‑D ≥ 26). 60h IV infusion; primary endpoint: HAM‑D change at 60 h; follow‑up to Day 30.

5/12 - While cross-trial comparison have always its (significant) limitations, as SubQ RE104 will ultimately be benchmarked against Sage's IV Brexanolone and oral Zuranolone (fair or not), I was interested in how the RE104 data set compared broadly to the Phase 2 and 3 data of.

4/12 - RE104 tolerability & dischargability.Most common TEAEs: nausea (44%), headache (34%); no SAEs reported. Preliminary lactation study: <0.1% of maternal 30 mg dose detected in breast milk metabolites. 93% discharge‑ready only 4h post‑dose (sitting between BPL-003 and

3/12 - RE104 topline efficacy.Primary met: −23 MADRS points at Day 7 with 30 mg vs −17.2 with 1.5 mg (Δ = −5.8; p = 0.0094). Onset by Day 1, maintained to Day 28. Response at Day 7: 77% (vs. 62% on active placebo); remission rate: 71% (vs 41%); remission and response

2/12 - RE104 Ph2 trial design.Multicenter, randomized, double‑blind, active dose‑controlled Ph2 (30 mg vs 1.5 mg) in 84 women with moderate–severe PPD (HAMD‑17 ≥ 24). Single subcutaneous dose; no psychotherapy; primary endpoint MADRS change at Day 7.

1/12 - Today, we saw another Phase 2 trial success of a psychedelic interventional psychiatry approach. Read on for the key data from the RE104 (5‑HT2A agonist) Phase 2 in PPD and how the data compares to Brexanolone and Zuranolone (both approved in PPD recently):

RT @atai_life: #Q2 2025 highlights: .✅Announced atai’s strategic combination with @BeckleyPsytech .✅Reported positive topline data in BPL-0….

$ATAI $CMPS $MNMD $GHRS.

5/ Who follows AbbVie? Full breakdown + company-by-company deep dive analysis here:

4/ 🏆 Leaders: J&J, AbbVie, Otsuka.⚠️ 'Dark horses': Lundbeck (+ Biogen).🤔 Others: BMS, Novartis, Roche, Takeda, BI (each for different reasons).

3/ We scored companies on 5 dimensions: strategic & cultural fit, psychedelic-specific capabilities, deal making pressure, balance sheet health, and M&A DNA.

2/ Late-stage trial wins, regulatory tailwinds, and a global mental health crisis affecting over 1 bn people are propelling psychedelics from fringe science to boardroom priority — and putting Big Pharma in deal mode.